Company Overview and News

 
PSU banks correct sharply after govt announces merger of Vijaya Bank, Dena Bank and BoB

2018-09-18 moneycontrol
The government announced another step toward reform of PSU banks on Monday with merger of three PSBs Bank of Baroda, Vijaya Bank and Dena Bank but that seems to have not received well by the market on Tuesday.
INDIANB UBNC 500116 IDBI 532737 532418 532814 CNRYY 532401 VIJAYABANK SYNDIBANK 532276 EMKAY 532121 532483 CANBK DENABANK ANDHRABANK

 
CBI to file fresh charge sheet against finance ministry officials in Vijay Mallya case: Report

2018-09-14 moneycontrol
The Central Bureau of Investigation (CBI) is planning to file a fresh charge sheet against finance ministry officials who were involved in the disbursal of loans from public sector banks to Vijay Mallya's Kingfisher Airlines, reported The Economic Times quoting people aware of the development.
532388 SYNDIBANK INDIANB IOB 532276 PNJZY 532461 532483 532814 PNB CANBK CNRYY

 
PNB recovers massive Rs 11,378 crore in first five months of FY19: Report

2018-09-10 moneycontrol
The Punjab National Bank (PNB) has recovered close to Rs 11,378 crore from its borrowers in the first five months of FY19.
PNJZY 532461 532483 BHUSANSTL PNB CANBK 500055 CNRYY

 
Canara Robeco Mutual Fund appoints Krishna Sanghavi as equity head

2018-09-04 moneycontrol
Canara Robeco Mutual Fund has appointed Krishna Sanghavi as head of equity with immediate effect, the fund house announced on September 4.
532483 CANBK CNRYY

 
Banks Board Bureau invites application for post of MD, CEO of Canara Bank

2018-09-04 livemint
New Delhi: Banks Board Bureau has invited applications for the post of managing director and chief executive director of Canara Bank for a three-year term.
532483 CANBK CNRYY

 
Banks Board Bureau invites application for post of MD, CEO of Canara Bank

2018-09-04 moneycontrol
Banks Board Bureau (BBB) has invited applications for the post of managing director and chief executive director of Canara Bank for a three-year term. The post of MD and CEO fell vacant at Canara Bank upon retirement of Rakesh Kumar Sharma on July 31, 2018.
532483 CANBK CNRYY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...